Gene · 8741
Papers1,439
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,439
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Atacicept: First Approval. | Drugs | 2026 | 42714746 | PubTator, text mining | PubMed |
| Atacicept in IgA nephropathy. | Expert Rev Clin Immunol | 2026 | 42710874 | PubTator, text mining | PubMed |
| TNFSF13 Drives Atherosclerosis Progression by Targeting Macrophage Senescence. | Int J Med Sci | 2026 | 42694578 | PubTator, text mining | PubMed |
| Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial. | Clin J Am Soc Nephrol | 2026 | 42275148 | PubTator, text mining | PubMed |
| Association between TNFSF13 SNPs and progression to end-stage renal disease in IgA nephropathy patients. | Int Urol Nephrol | 2026 | 42262683 | PubTator, text mining | PubMed |
| Zigakibart Potently Inhibits A Proliferation-Inducing Ligand-Mediated IgA Production, Addressing IgAN Pathogenesis Root Causes. | Kidney Int Rep | 2026 | 42205925 | PubTator, text mining | PubMed |
| Inflammatory Biomarkers Are Associated with Pain and Functional Impairment in Knee Osteoarthritis Patients: A Cross-Sectional Pilot Study. | J Clin Med | 2026 | 42123198 | PubTator, text mining | PubMed |
Efficacy, safety, and biomarker changes of B-cell activating factor and A proliferation-inducing ligand-targeted therapies in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials. | J Nephrol | 2026 | 42014363 | PubTator, text mining | PubMed |
| TNFSF13 insufficiency disrupts human colonic epithelial cell growth and associated B cell dynamics. | J Clin Invest | 2026 | 41919502 | PubTator, text mining | PubMed |
| Prediction of depressive episodes based on clinical features, cognitive characteristics, inflammation-related proteins, and EEG data. | Transl Psychiatry | 2026 | 41876463 | PubTator, text mining | PubMed |
| Proteome-wide Mendelian randomization identifies protein associations and therapeutic targets for B-cell malignancy. | Blood Neoplasia | 2026 | 41859349 | PubTator, text mining | PubMed |
| TDO2-Associated Tryptophan Metabolism Correlates with Impaired Tertiary Lymphoid Structure Maturation and Reduced B Cell Class Switching in Breast Cancer. | Oncol Res | 2026 | 41799509 | PubTator, text mining | PubMed |
| The Roles of A Proliferation-Inducing Ligand (APRIL) and B-Cell Activating Factor (BAFF) in IgA Nephropathy. | Am J Kidney Dis | 2026 | 41794353 | PubTator, text mining | PubMed |
| Plasma Proteomic Dynamics Preceding Glaucoma Reveal a 15-Year Pre-Diagnostic Window: Causal Insights and Predictive Utility in 45,850 Participants. | Invest Ophthalmol Vis Sci | 2026 | 41789843 | PubTator, text mining | PubMed |
| Genetic analysis of children with suspected immunodeficiency: mimickers of inborn errors of immunity. | Eur J Pediatr | 2026 | 41784637 | PubTator, text mining | PubMed |
| Pre-existing activation states shape functional heterogeneity of human Vγ9Vδ2 T cells. | Front Immunol | 2026 | 41777882 | PubTator, text mining | PubMed |
| An integrative ultrastructural and transcriptomic analysis of host-pathogen interactions with human brain microvascular endothelial cells during cryptococcal infection: a preliminary study. | Front Cell Infect Microbiol | 2026 | 41736794 | PubTator, text mining | PubMed |
| The Impact of Gut Microbiota on Immunoglobulin A Nephropathy through the Mediation of Specific Immune Cells: A Mendelian Randomization Study. | Kidney Dis (Basel) | 2026 | 41728059 | PubTator, text mining | PubMed |
| Comprehensive analysis of mitochondrial unfolded protein response related genes for prognosis and therapeutic response in pancreatic cancer. | Front Immunol | 2026 | 41727504 | PubTator, text mining | PubMed |
| Differential response to ofatumumab in anti-AChR and anti-MuSK positive myasthenia gravis patients: a single-center retrospective study. | Ther Adv Neurol Disord | 2026 | 41726319 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8741/papers